Identification

Name
Bepridil
Accession Number
DB01244  (APRD00727)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

Structure
Thumb
Synonyms
  • Bepadin
  • Bepridil
Product Ingredients
IngredientUNIICASInChI Key
Bepridil hydrochloride4W2P15D93M74764-40-2UEECHQPWQHYEDE-UHFFFAOYSA-N
International/Other Brands
Angopril / Cordium / Vascor
Categories
UNII
755BO701MA
CAS number
64706-54-3
Weight
Average: 366.5396
Monoisotopic: 366.26711372
Chemical Formula
C24H34N2O
InChI Key
UIEATEWHFDRYRU-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1

Pharmacology

Indication

For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).

Structured Indications
Not Available
Pharmacodynamics

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.

Mechanism of action

Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.

TargetActionsOrganism
AVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
USodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
UPotassium voltage-gated channel subfamily KQT member 1
inhibitor
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
UCalmodulin
binder
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
Absorption

Rapidly and completely absorbed after oral administration.

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

24-50 hours

Clearance
Not Available
Toxicity

There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Bepridil.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Bepridil.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bepridil.Experimental
AbirateroneThe serum concentration of Bepridil can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the hypotensive activities of Bepridil.Approved, Investigational
AcemetacinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bepridil.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Bepridil is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Bepridil.Approved, Investigational
AliskirenBepridil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
AmbrisentanBepridil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineBepridil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bepridil is combined with Amiloride.Approved
AmiodaroneThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Bepridil.Approved
AmobarbitalThe metabolism of Bepridil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Bepridil.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Bepridil.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bepridil is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Bepridil.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bepridil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Bepridil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Bepridil.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bepridil.Approved, Investigational
ArtemetherThe metabolism of Bepridil can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Bepridil.Approved
AtomoxetineThe metabolism of Bepridil can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Bepridil.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bepridil is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Bepridil.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Bepridil.Experimental
BarbitalThe metabolism of Bepridil can be increased when combined with Barbital.Illicit
BarnidipineBepridil may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Bepridil.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bepridil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bepridil.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Bepridil.Approved, Investigational
BetaxololThe metabolism of Bepridil can be decreased when combined with Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Bepridil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Bepridil.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Bepridil.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bepridil.Approved
BoceprevirThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bepridil is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Bepridil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved
BQ-123Bepridil may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Bepridil.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Bepridil.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bepridil.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bepridil.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bromocriptine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Bepridil.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bepridil is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Bepridil.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bupivacaine.Approved, Investigational
BupranololBepridil may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Bepridil can be decreased when combined with Bupropion.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Bepridil.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Bepridil.Approved
CadralazineCadralazine may increase the hypotensive activities of Bepridil.Experimental
CafedrineBepridil may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Canagliflozin.Approved
CandesartanBepridil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Bepridil.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Bepridil.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Bepridil.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Bepridil.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bepridil.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Bepridil.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bepridil.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Bepridil.Approved, Investigational
CaseinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Bepridil.Approved
CelecoxibThe metabolism of Bepridil can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBepridil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Bepridil.Approved
ChloroquineThe metabolism of Bepridil can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Bepridil.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Bepridil is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bepridil.Approved
CholecalciferolThe metabolism of Bepridil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineBepridil may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Bepridil.Approved, Investigational
CilazaprilBepridil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Bepridil can be decreased when combined with Cinacalcet.Approved
CisaprideCisapride may increase the QTc-prolonging activities of Bepridil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Bepridil can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Bepridil can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Bepridil can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Bepridil can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Bepridil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.Approved
CloranololBepridil may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Bepridil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clozapine.Approved
CobicistatThe serum concentration of Bepridil can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bepridil can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bepridil.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Bepridil is combined with Conivaptan.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Bepridil.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Bepridil.Approved
CyclopenthiazideBepridil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bepridil.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Dapagliflozin.Approved
DarifenacinThe metabolism of Bepridil can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bepridil can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Bepridil.Approved, Investigational
DelamanidBepridil may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelaprilBepridil may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Bepridil can be decreased when combined with Delavirdine.Approved
DeserpidineBepridil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Desflurane.Approved
DesipramineThe metabolism of Bepridil can be decreased when combined with Desipramine.Approved, Investigational
DeutetrabenazineBepridil may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bepridil.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Bepridil.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineBepridil may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Bepridil.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Bepridil.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Bepridil can be decreased when combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bepridil.Approved
DosulepinThe metabolism of Bepridil can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Bepridil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.Approved, Investigational
DronedaroneThe metabolism of Bepridil can be decreased when combined with Dronedarone.Approved
DuloxetineBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Bepridil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved
EfavirenzThe risk or severity of ventricular arrhythmias can be increased when Efavirenz is combined with Bepridil.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Bepridil.Approved
EfonidipineBepridil may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Bepridil can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bepridil.Approved, Vet Approved
EnalaprilatBepridil may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bepridil.Experimental
EpanololBepridil may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bepridil.Approved
EprosartanEprosartan may increase the hypotensive activities of Bepridil.Approved
EsmololThe risk or severity of adverse effects can be increased when Bepridil is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bepridil is combined with Etacrynic acid.Approved, Investigational
EtravirineThe serum concentration of Bepridil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved
FelodipineFelodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Bepridil.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Bepridil.Experimental
Ferulic acidBepridil may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Bepridil is combined with Fimasartan.Approved, Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Bepridil.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Bepridil.Approved, Investigational
FluoxetineThe metabolism of Bepridil can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Bepridil.Experimental
FluvoxamineThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bepridil.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bepridil is combined with Furosemide.Approved, Vet Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Bepridil.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bepridil.Approved
GuanazodineBepridil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bepridil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanoclorBepridil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBepridil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBepridil may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Bepridil.Experimental
HaloperidolThe metabolism of Bepridil can be decreased when combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Bepridil.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Bepridil.Experimental
HexamethoniumBepridil may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Bepridil.Approved, Investigational
HexobarbitalThe metabolism of Bepridil can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bepridil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Bepridil.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bepridil.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Bepridil is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Bepridil is combined with Imipramine.Approved
IndapamideIndapamide may increase the hypotensive activities of Bepridil.Approved
IndenololBepridil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bepridil can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Bepridil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Bepridil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bepridil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bepridil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Bepridil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Bepridil can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bepridil.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Bepridil.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Bepridil.Investigational
KetoconazoleThe metabolism of Bepridil can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Bepridil.Approved
LacidipineBepridil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bepridil.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Bepridil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobupivacaine.Approved, Investigational
LevodopaBepridil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bepridil is combined with Levosimendan.Approved, Investigational
LinsidomineBepridil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Bepridil.Approved, Investigational
LofexidineBepridil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Bepridil can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bepridil can be decreased when combined with Lorcaserin.Approved
LosartanLosartan may increase the hypotensive activities of Bepridil.Approved
LumefantrineThe metabolism of Bepridil can be decreased when combined with Lumefantrine.Approved
MacimorelinBepridil may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MacitentanBepridil may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineBepridil may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bepridil is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bepridil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bepridil.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Bepridil.Experimental
MethadoneThe metabolism of Bepridil can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methazolamide.Approved
MethohexitalThe metabolism of Bepridil can be increased when combined with Methohexital.Approved
MethoserpidineBepridil may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bepridil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bepridil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bepridil.Approved, Investigational
MethylphenobarbitalThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Bepridil.Approved
MetolazoneMetolazone may increase the hypotensive activities of Bepridil.Approved
MetoprololThe metabolism of Bepridil can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineBepridil may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Bepridil.Experimental
MibefradilBepridil may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Bepridil.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Bepridil can be decreased when combined with Midostaurin.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Bepridil.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Bepridil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bepridil.Approved, Investigational
MirabegronThe metabolism of Bepridil can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bepridil.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bepridil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Bepridil.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bepridil.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Bepridil.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Bepridil is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Bepridil.Approved, Investigational
MuzolimineBepridil may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Bepridil.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Bepridil.Approved
NafcillinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Bepridil.Approved
NaftopidilBepridil may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bepridil.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Bepridil.Approved
NebivololBepridil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Bepridil can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bepridil.Withdrawn
NicardipineThe metabolism of Bepridil can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Bepridil.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Bepridil.Experimental
NiguldipineBepridil may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Bepridil.Investigational
NilotinibThe metabolism of Bepridil can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineBepridil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Bepridil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bepridil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitroglycerin.Approved, Investigational
NitroprussideBepridil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitrous acid.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Bepridil.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Bepridil.Approved, Vet Approved
ObinutuzumabBepridil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Bepridil.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Bepridil.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Bepridil.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Bepridil.Approved
OxprenololBepridil may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Bepridil is combined with Paclitaxel.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Bepridil.Investigational
PanobinostatThe serum concentration of Bepridil can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Bepridil is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Bepridil.Approved
ParoxetineThe metabolism of Bepridil can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved
Peginterferon alfa-2bThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololBepridil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Bepridil.Approved, Investigational
PentobarbitalThe metabolism of Bepridil can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bepridil.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bepridil.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Bepridil.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bepridil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bepridil.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bepridil.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bepridil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bepridil.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bepridil.Approved
PinacidilPinacidil may increase the hypotensive activities of Bepridil.Approved
PindololPindolol may increase the hypotensive activities of Bepridil.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Bepridil.Approved
PitolisantThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Bepridil.Withdrawn
Platelet Activating FactorBepridil may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBepridil may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Bepridil.Approved
PrimidoneThe metabolism of Bepridil can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Bepridil.Approved, Investigational
PromazineThe metabolism of Bepridil can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Bepridil is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Bepridil.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bepridil.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Bepridil.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Bepridil is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bepridil.Approved, Investigational
QuinidineThe metabolism of Bepridil can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Bepridil can be decreased when combined with Quinine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Bepridil.Experimental
RamiprilRamipril may increase the hypotensive activities of Bepridil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bepridil.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Bepridil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Bepridil.Approved
RescinnamineBepridil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bepridil.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Bepridil.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Bepridil.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Bepridil.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Bepridil.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bepridil.Approved, Investigational
RiociguatBepridil may increase the hypotensive activities of Riociguat.Approved
RisperidoneBepridil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Bepridil can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBepridil may increase the hypotensive activities of Rituximab.Approved
RolapitantThe metabolism of Bepridil can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Bepridil can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bepridil is combined with Rotigotine.Approved
RucaparibThe metabolism of Bepridil can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Bepridil.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Bepridil.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
SaprisartanBepridil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirBepridil may increase the arrhythmogenic activities of Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Bepridil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
SelexipagBepridil may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Bepridil.Approved, Investigational
SertralineThe metabolism of Bepridil can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bepridil is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Bepridil.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Bepridil.Approved, Investigational
SitaxentanBepridil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Bepridil is combined with Sotalol.Approved
SpiraprilBepridil may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Spironolactone.Approved
StiripentolThe metabolism of Bepridil can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bepridil is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Bepridil.Approved
TadalafilTadalafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
TalinololBepridil may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Bepridil.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Bepridil.Approved, Investigational
TelaprevirThe serum concentration of Bepridil can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelmisartanTelmisartan may increase the hypotensive activities of Bepridil.Approved, Investigational
TemocaprilBepridil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Bepridil.Approved
TerbinafineThe metabolism of Bepridil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Bepridil.Approved
TerlipressinBepridil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineBepridil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bepridil is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineBepridil may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Bepridil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Bepridil can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Bepridil can be decreased when combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Bepridil.Approved
TiboloneBepridil may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Bepridil can be decreased when combined with Ticlopidine.Approved
TicrynafenBepridil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Bepridil.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Bepridil.Approved
TipranavirThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Bepridil.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Bepridil.Approved, Investigational, Vet Approved
TolonidineBepridil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bepridil.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bepridil.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Bepridil.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Bepridil.Approved
TranylcypromineThe metabolism of Bepridil can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Bepridil.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bepridil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bepridil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Bepridil is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Bepridil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bepridil.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Bepridil.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
UnoprostoneBepridil may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Bepridil.Investigational
ValsartanValsartan may increase the hypotensive activities of Bepridil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bepridil.Approved
VenlafaxineThe metabolism of Bepridil can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Bepridil is combined with Verapamil.Approved
VincamineBepridil may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Bepridil.Approved, Investigational
VinpocetineBepridil may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Bepridil.Approved, Investigational
XipamideBepridil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBepridil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Bepridil.Approved, Investigational, Vet Approved
ZiprasidoneThe metabolism of Bepridil can be decreased when combined with Ziprasidone.Approved
ZofenoprilBepridil may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
  • Alcohol may further decrease blood pressure and increase dizziness and drowsiness
  • Take with food to reduce nausea.

References

Synthesis Reference

Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".

General References
Not Available
External Links
Human Metabolome Database
HMDB0015374
KEGG Compound
C06847
PubChem Compound
2351
PubChem Substance
46506353
ChemSpider
2261
BindingDB
78577
ChEBI
3061
ChEMBL
CHEMBL1008
Therapeutic Targets Database
DAP000525
PharmGKB
PA164754755
IUPHAR
2337
Guide to Pharmacology
GtP Drug Page
HET
BEP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bepridil
ATC Codes
C08EA02 — Bepridil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)128Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
water solubilitySlightly solubleNot Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP5.33ALOGPS
logP5.49ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.12 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9859
Blood Brain Barrier+0.9003
Caco-2 permeable+0.5593
P-glycoprotein substrateSubstrate0.7013
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6774
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5495
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5636
Ames testNon AMES toxic0.67
CarcinogenicityNon-carcinogens0.8688
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.4903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dialkylarylamines / Benzylamines / Aniline and substituted anilines / Aralkylamines / N-alkylpyrrolidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylbenzamine / Benzylamine / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine / N-alkylpyrrolidine / Pyrrolidine / Tertiary amine / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amine, pyrrolidines (CHEBI:3061)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Kovacic H, Gallice P, Crevat A: Inhibition of sodium pump by bepridil. An in vitro and microcalorimetric study. Biochem Pharmacol. 1992 Oct 20;44(8):1529-34. [PubMed:1329768]
  2. Raess BU, Record DM: Inhibition of erythrocyte Ca2(+)-pump by Ca2+ antagonists. Biochem Pharmacol. 1990 Dec 1;40(11):2549-55. [PubMed:2148481]
  3. Smith SJ, England PJ: The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol. 1990 Aug;100(4):779-85. [PubMed:2207500]
  4. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  5. Fuchs J, Mainka L, Reifart N, Zimmer G: Effects of bepridil on heart mitochondrial membrane and the isolated rat heart preparation. Arzneimittelforschung. 1986 Feb;36(2):209-12. [PubMed:2938592]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modul...
Gene Name
KCNQ1
Uniprot ID
P51787
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 1
Molecular Weight
74697.925 Da
References
  1. Chouabe C, Drici MD, Romey G, Barhanin J: Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie. 2000 Jan-Feb;55(1):195-202. [PubMed:10860024]
  2. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, Takano M, Niwano S, Izumi T: Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol. 2004 Feb;43(2):178-82. [PubMed:14716203]
  3. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 1998 Oct;54(4):695-703. [PubMed:9765513]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001 Sep 28;506(1):51-4. [PubMed:11591369]
  2. Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11. [PubMed:12060657]
  3. MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70. [PubMed:2351672]
  4. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:29